Evidence map›Paper›PMID 33152019›Full record

ArticlePloS one2020

Variant analysis of 1,040 SARS-CoV-2 genomes.

Eric C Rouchka, Julia H Chariker, Donghoon Chung

Abstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. The battle between host and SARS-CoV-2: Innate immunity and viral evasion strategies.Molecular therapy : the journal of the American Society of Gene Therapy · 2022
    Review
  6. Rapid automated validation, annotation and publication of SARS-CoV-2 sequences to GenBank.Database : the journal of biological databases and curation · 2022
    Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Novel and emerging mutations of SARS-CoV-2: Biomedical implications.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021
    Review
  16. Article
  17. Review
  18. Article
  19. SARS-CoV-2: An Update on Genomics, Risk Assessment, Potential Therapeutics and Vaccine Development.International journal of environmental research and public health · 2021
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Eric C RouchkaDepartment of Computer Science and Engineering, University of Louisville, Louisville, Kentucky, United States of America.ORCID 0000-0003-3487-6572
Julia H CharikerKentucky Biomedical Research Infrastructure Network Bioinformatics Core, University of Louisville, Louisville, Kentucky, United States of America.
Donghoon ChungDepartment of Microbiology and Immunology, University of Louisville, Louisville, Kentucky, United States of America.

Funding

WKU Lead Faculty AwardP20GM103436 · NIGMS · UNIVERSITY OF LOUISVILLE · PI ERIC C ROUCHKA · 2012 to 2026
$60.1M
NIGMS NIH HHS P20 GM103436
6 · The paper itself

Abstract

The severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) viral genome is an RNA virus consisting of approximately 30,000 bases. As part of testing efforts, whole genome sequencing of human isolates has resulted in over 1,600 complete genomes publicly available from GenBank. We have performed a comparative analysis of the sequences, in order to detect common mutations within the population. Analysis of variants occurring within the assembled genomes yields 417 variants occurring in at least 1% of the completed genomes, including 229 within the 5' untranslated region (UTR), 152 within the 3'UTR, 2 within intergenic regions and 34 within coding sequences.

Indexed as

Genome, ViralMutation3' Untranslated Regions5' Untranslated RegionsBetacoronavirusGenetic LinkageLinkage DisequilibriumLod ScoreSARS-CoV-2Sequence Analysis, RNAWhole Genome Sequencing3' Untranslated Regions5' Untranslated Regions

Identifiers

PMID33152019
PMCPMC7643988

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.